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or p16 negative cells, indicating a differential role of p16 
protein expression depending on its localization. Strikingly, 
cells expressing nuclear p16 (p16-NLS) -although showing a 
similar level of gH2AX induction- were characterized with 
lower number RAD51 foci formation compared to cells 
expressing cytoplasmic p16 (p16-NES), suggesting an impaired 
HRR. 
 
Conclusion: Cellular p16 localization is an important factor 
for stratification of HNSCC patients with nuclear p16 
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Purpose or Objective: To retrospectively assess the 
prognostic value of the potential biomarkers, i.e. chemokine 
receptor CXCR4, its ligand CXCL12 (SDF1), and nuclear EGFR 
expression in a cohort of 201 patients with locally advanced 
HNSCC. Patients were treated between 2005 and 2011 in 8 
German cancer centers, as part of a multicenter biomarker 
study of the German Cancer Consortium Radiation Oncology 
Group (DKTK-ROG). Experimental data and first clinical 
observations suggest that activation of CXCR4 and SDF1 
signaling pathway and nuclear location of EGFR are 
implicated in tumour cell proliferation, cellular survival, 
tumour progression, worse overall survival, metastasis and 
enhanced treatment resistance in different tumour types. 
 
Material and Methods: Patients with locally advanced SCC of 
the oral cavity, oropharynx and hypopharynx were treated 
with resection and adjuvant RT and Cisplatin-based CT. 
Tissue micro-arrays (TMAs) were generated from surgical 
specimens and evaluated for the expression of the 
biomarkers by immunofluorescence with a semi-quantative 
method, based on their cellular location (membranous, 
intracellular, nuclear), extent of expression on TMA area and 
staining intensity. The results of the biomarker analysis along 
with the clinical parameters were then correlated with the 
clinical outcome. 
 
Results: In univariate analysis, tumours with either SDF1 or 
CXCR4 intracellular overexpression displayed a significant 
negative correlation with loco-regional control (LCR) (HR: 
2.52, p=0.01 and HR: 1.96, p=0.05 respectively). No 
correlation was observed for the nuclear expression of EGFR 
(HR: 0.85, p= 0.67), membranous expression of SDF1 (p=0.73) 
or CXCR4 (p=0.38). Tumours with intracellular co-expression 
of both SDF1 and CXCR4 were significantly correlated with 
poor LRC (HR: 2.72, p=0.01). Previously published data from 
the same cohort, showed that absence of p16 (negative HPV 
status) was correlating with poor LRC. Importantly, increased 
expression of SDF1 or co-expression with CXCR4 could 
identify a group of patients with significantly worse outcome 
within the HPV negative group (p=0.01). Multivariate cox 
regression analysis including HPV status, tumour localisation, 
tumour volume and the respective biomarkers indicated a 
significant independent role of SDF1 (HR: 2.20, p=0.04) and 
co-expression with CXCR4 (HR: 2.19, p=0.05) on LRC. 
 
Conclusion: In summary, pre-treatment overexpression of 
CXCR4/SDF1 is an independent negative prognostic factor for 
the outcome of patients with locally advanced HNSCC who 
receive surgery and standard RT-CT. Further investigation in 
a cohort of patient receiving primary RT-CT and a 
prospective validation study is currently ongoing. 
SDF1/CXCR4 appears to be a promising biomarker for 
treatment individualization, in particular in HPV negative 
advanced HNSCC patients and supports strategies using 
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Purpose or Objective: Radio(chemo)therapy is a crucial 
treatment modality for head and neck squamous cell 
carcinoma (HNSCC). Radiotherapy resistance is a major 
reason for therapy failure and, therefore, predictive 
biomarkers for therapy response are urgently needed. DNA 
gains on chromosome 16q23-24 have been shown to be 
associated with genomic amplification of the FancA gene and 
to correlate with reduced progression-free survival of HNSCC 
patients after radiotherapy. This study aimed to analyze the 
effects of the potential predictive marker FancA on radiation 
sensitivity in vitro, to characterize the underlying molecular 
mechanisms, and to evaluate the clinical relevance in HNSCC. 
 
Material and Methods: We generated FancA overexpressing 
human oral keratinocytes (OKF6/FancA) and analyzed several 
endpoints upon irradiation. To identify signaling pathways 
involved in FancA-mediated resistance, global transcriptome 
analyses were performed after irradiation with 4 Gy or sham-
irradiation followed by pathway enrichment analysis and 
reconstruction of function interaction networks. The clinical 
relevance of the cytogenetic marker 16q23-24, the FancA 
gene and our in vitro results was analyzed in data of 113 
radiotherapy-treated patients from The Cancer Genome Atlas 
(TCGA) HNSCC cohort (Nature, 2015). 
 
Results: Overexpression of FancA resulted in enhanced 
survival after in vitro irradiation. Moreover, FancA 
overexpressing cells demonstrated accelerated DNA damage 
repair mechanisms paralleled by increased repair fidelity: 
enhanced p53 and p21 response, accelerated kinetics in the 
disappearance of γ-H2AX DNA damage repair foci, faster 
pATM translocation, reduced accumulation of chromosomal 
translocations, but no increase in FancD2 mono-
ubiquitinylation. Global mRNA expression analyses identified 
interferon signaling as a major candidate pathway, which was 
affected by FancA overexpression. Functional interaction 
networks of genes deregulated upon irradiation pointed to 
pathways exclusively involved in FancA-mediated 
radioresistance including the senescence-associated secretory 
phenotype (SASP). Increased levels of basal and irradiation-
induced cellular senescence accompanied by enforced SASP 
formation further support their potential involvement in 
FancA-mediated radiation resistance. The clinical relevance 
of our findings was validated in the data of 113 radiotherapy-
treated patients of the TCGA HNSCC cohort demonstrating 
the association of chromosomal gains on 16q24.3 with 
increased FancA mRNA expression levels and impaired overall 
survival. Furthermore, the translation of our in vitro model 
derived results into the HNSCC patient specimens revealed 
similar gene expression changes linked to FancA 
overexpression. 
 
Conclusion: Our data suggest an important role for FancA in 
cellular mechanisms of radioresistance in HNSCC. 
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Purpose or Objective: The addition of hypoxia modifiers 
carbogen and nicotinamide (CON) to radiotherapy (RT) 
improved overall survival in bladder cancer patients enrolled 
in the BCON phase III clinical trial. We investigated whether 
the expression of miR-210 in the BCON patient samples 
reflects hypoxia and predicts benefit from hypoxia-
modification. 
 
Material and Methods: The retrospective study involved 183 
T1-T4b patients: 86 received RT+CON and 97 received RT 
alone. Formalin-fixed samples taken prior to radiotherapy 
were available and RNA extracted. Customised TaqMan plates 
were used to assess miR-210 expression using quantitative 
real-time PCR. Patients were classified as low miR-210 
(<median expression) or high miR-210 (≥ median). Data on 
other hypoxia biomarkers were available for comparison. 
 
Results: Patients with high miR-210 had a trend towards 
improved five-year OS with RT+CON (53.2%) compared with 
RT alone (37.8%; HR 1.68, 95% CI 0.95-2.95, P=0.08). No 
benefit was seen with low miR-210 (HR 1.02, 95% CI 0.58-
1.79, P=0.97). High expression of miR-210 was also associated 
with high HIF-1α protein (P=0.0008), CA9 protein (P=0.004), 
Glut-1 protein (P=0.02), expression of a 26-gene hypoxia 
signature (P=0.01), tumour necrosis (P=0.04) and concurrent 
pTis (P=0.03). 
 
Conclusion: High miR-210 expression may reflect tumour 
hypoxia and should be investigated further as a potential 
biomarker to identify bladder cancer patients who would 
benefit from hypoxia-modifying therapies. 
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Purpose or Objective: The DNA cytosine deaminase APOBEC3 
proteins catalyze deamination of cytidines in single-stranded 
DNA, providing innate protection against retroviral 
replication. Recent studies have implicated APOBEC3B as a 
major source of mutation in breast cancer, suggesting a role 
for these enzymes in tumor initiation and/or progression. 
APOBEC3B expression levels were earlier found to correlate 
with poor outcomes for patients with estrogen receptor 
positive breast cancer, especially after Tamoxifen. Given its 
role in mutagenesis, we set out to assess whether APOBEC3B 
associates with radiosensitivity in breast cancer. 
 
Material and Methods: MCF7 breast cancer cells were 
cultured radioresistant by daily 2 Gy treatments or 
tamoxifen-resistant by continuous culturing in up to 10 uM 4-
OH-tamoxifen. The effect of irradiation on expression of 
APOBECs was assessed by RNAseq and qPCR in radiosensitive 
and radioresistant MCF7, and by qPCR in radioresistant MDA-
MB231 cells. Furthermore, we studied a retrospective cohort 
of 535 non-systemically treated breast cancer patients. The 
predictive power of APOBEC3B was assessed in patients that 
did or did not receive radiotherapy as part of their primary 
therapy. Next, we suppressed endogenous APOBEC3B in MCF-
